RBM3 and neoplasm: It should also be emphasized that, in a translational context, the proposal that RBM3 is a proto-oncogene activated in response to adverse cellular conditions [27] does not contradict the findings that its presence in an established tumor is associated with a favourable patient outcome as such findings would not have taken patient treatment into account.